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ORIGINAL ARTICLE
Glutamate/glutamine and neuronal integrity in adults with
ADHD: a proton MRS study
S Maltezos1,2, J Horder2, S Coghlan2, C Skirrow3, R O'Gorman4, TJ Lavender2, MA Mendez2,5, M Mehta4, E Daly2, K Xenitidis1,2,
E Paliokosta1, D Spain2,5, M Pitts1, P Asherson1,3, DJ Lythgoe4, GJ Barker4 and DG Murphy2,5,6
There is increasing evidence that abnormalities in glutamate signalling may contribute to the pathophysiology of attention-deﬁcit
hyperactivity disorder (ADHD). Proton magnetic resonance spectroscopy ([1H]MRS) can be used to measure glutamate, and also its
metabolite glutamine, in vivo. However, few studies have investigated glutamate in the brain of adults with ADHD naive to
stimulant medication. Therefore, we used [1H]MRS to measure the combined signal of glutamate and glutamine (Glu+Gln;
abbreviated as Glx) along with other neurometabolites such as creatine (Cr), N-acetylaspartate (NAA) and choline. Data were
acquired from three brain regions, including two implicated in ADHD—the basal ganglia (caudate/striatum) and the dorsolateral
prefrontal cortex (DLPFC)—and one ‘control’ region—the medial parietal cortex. We compared 40 adults with ADHD, of whom 24
were naive for ADHD medication, whereas 16 were currently on stimulants, against 20 age, sex and IQ-matched healthy controls.
We found that compared with controls, adult ADHD participants had a signiﬁcantly lower concentration of Glx, Cr and NAA in the
basal ganglia and Cr in the DLPFC, after correction for multiple comparisons. There were no differences between stimulant-treated
and treatment-naive ADHD participants. In people with untreated ADHD, lower basal ganglia Glx was signiﬁcantly associated with
more severe symptoms of inattention. There were no signiﬁcant differences in the parietal ‘control’ region. We suggest that
subcortical glutamate and glutamine have a modulatory role in ADHD adults; and that differences in glutamate–glutamine levels
are not explained by use of stimulant medication.
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INTRODUCTION
Attention-deﬁcit/hyperactivity disorder (ADHD) is a neurodevelop-
mental syndrome with childhood onset that affects ~ 5% of
children and 2.5% of adults.1 The condition is characterised by
pervasive, developmentally inappropriate levels of hyperactivity,
impulsivity and inattention. ADHD leads to signiﬁcant functional
impairments and economic burden.2 ADHD in adults has
historically been underdiagnosed and has received less research
attention than childhood ADHD, but its importance is becoming
more widely recognised.3
There is substantial evidence that individuals with ADHD have
abnormalities in brain anatomy and function,4 and perhaps
especially in dopamine neurotransmission5,6 within the prefrontal
cortex (PFC) and the basal ganglia—areas known to be involved in
both attention and the regulation of behaviour.
One line of evidence in favour of the ‘dopamine hypothesis’ of
ADHD comes from the efﬁcacy of cathecholaminergic stimulant
drugs, such as methylphenidate and amphetamine, in relieving
ADHD symptoms. Stimulants enhance synaptic dopamine (and
noradrenaline) levels by blocking dopamine reuptake transporters
(DAT) and, in the case of amphetamine, by promoting dopamine
release from presynaptic neurons.7
However, although stimulants are superior to placebo in
improving ADHD symptoms in the short term,8 they are not
effective in all cases. For instance, it is estimated that stimulants
produce complete remission in ~ 30% of cases, with substantial
but partial improvement in another 40%, and little or no beneﬁt in
30%.9 Hence, deﬁcient dopamine neurotransmission seems
unlikely to be responsible for all cases of this heterogeneous
disorder. In order to develop effective treatments for ADHD cases
refractory to current medications, therefore, it may be necessary to
look beyond dopamine.
Impaired glutamate signalling is another possible underlying
abnormalities in (some cases of) ADHD, and an emerging
treatment target.10 Glutamate is an amino acid involved in
excitatory neurotransmission.11 Further, glutamate and dopamine
interact, with glutamate modulating dopamine release in corti-
costriatal pathways and vice versa.12
There is some—albeit preliminary—evidence to suggest
glutamatergic involvement in ADHD. For example, genetic studies
have reported an association between ADHD and a number of
glutamate receptor gene variants.13 Further, some animal models
suggest that altered glutamate regulation of the dopamine
system14 underpins the functional deﬁcits associated with ADHD.
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Until relatively recently, however, it was impractical to measure
human brain glutamate in vivo.
Proton magnetic resonance spectroscopy ([1H]MRS) can be
used to quantify the combination of glutamate and its metabolic
product glutamine (Glu+Gln, henceforth abbreviated Glx) in
addition to other metabolites of potential clinical importance,
such as choline (Cho) containing compounds, creatine (Cr) and
phosphocreatine (Cr+PCr, hereafter abbreviated Cr), and N-
acetylaspartate (NAA). It is generally accepted that Cr is involved
in phosphate metabolism and reﬂects energy use and storage by
neurons, whereas Cho is a measure of membrane synthesis and
turnover, and NAA is a marker of neuronal density and/or
mitochondrial function.15
Prior [1H]MRS studies of Glx and other metabolites in adults
with ADHD16,17 (see the Discussion for details) have reported
mixed ﬁndings. For example, some reported increases in Glx,18
whereas others found decreases.19 These studies were valuable
ﬁrst steps. However, they suffered from a number of limitations,
for instance, most did not control for possible effects of prior use
of ADHD medication (which has been shown to affect Glx and
other metabolite levels.20)
Therefore, we investigated differences in brain glutamate/
glutamine and other key neurometabolites in adults with ADHD
and controls. In addition, we recruited both treatment-naive and
stimulant-medicated ADHD individuals in order to allow us to
ascertain whether any differences observed were associated with
pharmacological confounds.
We acquired spectra from three [1H]MRS voxels, with the
following locations: the caudate nucleus/striatum (basal ganglia),
the dorsolateral PFC (DLPFC) and the medial parietal cortex. The
caudate/striatum and the DLPFC were chosen on the grounds that
abnormalities in both of these interconnected regions have been
previously implicated in ADHD.21 Moreover, these two selected
areas are known to be involved in processes relevant to the
symptoms of ADHD: the caudate/striatum is responsible for the
regulation of attention,22,23 whereas the DLPFC is a key part of the
executive control network in the brain.24,25
We selected the third area, the medial parietal cortex, as a
‘control’ region, as the structure and neurochemistry of this area
have not previously been linked to ADHD. This was included as we
wished to investigate whether any abnormalities seen in these
disease-linked areas reﬂected speciﬁc local changes, or more
widespread differences in metabolite levels.
MATERIALS AND METHODS
Participants
We included 60 adults: 40 with ADHD and 20 matched healthy controls
(Table 1). The ADHD cohort was comprised of two groups—24 individuals
who were stimulant naive and 16 individuals who were currently receiving
stimulant (methylphenidate or dextroamphetamine) treatment (the pre-
scribed dose of stimulants was not recorded). We included only right-
handed participants in order to avoid possible effects of lateralisation,
given that the [1H]MRS voxels in this study were unilateral.
ADHD participants were recruited from the Adult ADHD Service at the
Maudsley Hospital in London, a specialist clinic providing diagnostic
assessment and treatment for adults with ADHD referred from across the
United Kingdom.
Diagnosis was performed by a consultant psychiatrist specialising in
adult ADHD. Diagnosis was informed by pre-assessment questionnaires
and by an in-depth clinical interview based around the ‘Conners Adult
ADHD Diagnostic Interview DSM-IV’, a structured clinical interview based
on DSM-IV (Diagnostic and Statistical Manual, 4th Edition) criteria.26
Using Part II of ‘Conners Adult ADHD Diagnostic Interview DSM-IV’, the
‘Diagnostic Criteria Interview for DSM-IV’, information was gathered on
current symptoms as well as on the age of onset, pervasiveness and level
of impairment for each symptom present. Diagnosis was made if there was
clear evidence of clinically signiﬁcant impairment in more than two
domains (social, academic or occupational functioning) in accordance with
DSM-IV criteria. Therefore, all 40 participants with ADHD meet the DSM-IV
diagnostic criteria for ADHD. In terms of clinical subtypes, these, 22
individuals meet the criteria for Combined Type ADHD and 18 individuals
for inattentive type; none met criteria for hyperactive type. However, it is
noteworthy that we have not conducted subgroup analyses, as we believe
that correlational analysis using dimensional symptom measures is more
appropriate.
The assessment also included obtaining a detailed account of past
psychiatric history, developmental history, medical history and a mental
state examination. Information regarding past psychiatric history was also
provided by the referring clinician. Pre-assessment questionnaires included
the Barkley Scales27, which provides both self- and informant assessment
for (a) adulthood and (b) childhood symptoms.
Exclusion criteria for the ADHD group included the current presence of
any other DSM-IV Axis I psychiatric disorder; an autistic spectrum disorder;
a tic disorder; past or current substance abuse; signiﬁcant medical or
neurological illness affecting brain function; and the use of any
psychotropic medication, other than stimulants, in the previous 6 months.
Although we included ADHD patients only if they had no current
psychiatric comorbidity, 22 out of the 40 ADHD participants had a prior
history of a psychiatric disorder(s) other than ADHD, including depression,
anxiety and personality disorder. Furthermore, 14 ADHD patients had been
exposed to psychotropic medication other than stimulants in the past,
mainly antidepressants.
Healthy controls had no history of any psychiatric disorder, and were
naive to psychoactive medication.
Ethical approval for this study was provided by South London and
Maudsley/Institute of Psychiatry (SLaM/IoP) National Health Service
Research Ethics Committee, study reference 1997/087. After complete
description of the study to the subjects, written informed consent was
obtained.
Design and procedure
[1H]-MRS data acquisition. [1H]MRS data were acquired on a 1.5T GE HDx
Magnetic Resonance Imaging (MRI) scanner (GE Medical Systems,
Milwaukee, WI, USA) equipped with TwinSpeed gradients.
The scanning protocol included a structural MRI scan for the localisation
of the spectroscopy voxels in each participant, namely a three-dimensional
Table 1. Participant characteristics
Controls
(n= 20)
ADHD (n= 40)
Medication
naive
(n= 24)
Medicated (n=16)
Age 33 (7) 29 (9) 33 (5)
Full-scale IQ 116 (22) 104 (14) 114 (16)
Barkley (current,
self-report) Total
Inattentive
Score
NA 22.3 (3.1) 22.6 (3.7)
Barkley (current,
self-report) Total
Hyperactive
Score
NA 18.0 (5.3) 18.3 (7.0)
Sex (male/
female)
15/5 17/7 14/2
Stimulant
medication
Never Never Current methylphenidate
(n= 15); current
dextroamphetamine
(n= 1)
Duration of
stimulant
treatment,
weeks
NA NA 86 (180)
Abbreviations: ADHD, attention-deﬁcit hyperactivity disorder; NA, not
applicable. All data are given as group means (with s.d. in brackets). Note
that data on ADHD participants are presented separately for the
Medication naive and Medicated subgroups.
Glutamate/glutamine in ADHD
S Maltezos et al
2
Translational Psychiatry (2014), 1 – 8 © 2014 Macmillan Publishers Limited
fast inversion-recovery prepared spoiled gradient echo (SPGR) acquisition
with number of slices = 146, slice thickness = 1.2 mm, inversion time= 300
ms, repetition time= 11ms, echo time= 5ms, ﬁeld of view= 310mm, ﬂip
angle = 18°, matrix = 256× 160 over a 310× 194mm ﬁeld of view, giving
1.20× 1.20 × 1.20mm3 voxels. Full Scale IQ was measured using the
Wechsler Abbreviated Scale of Intelligence.
Three single voxel [1H]MRS spectra were then acquired, using a point-
resolved spectroscopy sequence. Point-resolved spectroscopy parameters
were: repetition time= 3000ms and echo time=30ms. A total of 72 (for
the parietal) or 104 (for basal ganglia and DLPFC voxels) repeat
observations were averaged to produce the ﬁnal spectrum. In addition
to this, eight observations without water suppression were averaged and
used for absolute water scaling.
The ﬁrst voxel (20x20 × 20mm3) was placed in the left medial parietal
lobe. The second voxel (20x20× 15mm3) was positioned in left basal
ganglia to include parts of the head of the caudate, the anterior putamen
and the internal capsule. The last voxel (16x24× 20mm3) was placed in the
left DLPFC. See Figure 1 for an illustration of the location of these voxels.
Standardised placement procedures were used to ensure the anatomical
comparability of the voxels between participants. For example, for the
basal ganglia voxel, on the structural MRI, the axial slice where the width of
the putamen in the right–left direction was widest was selected. The
centre of the voxel was placed on this slice, such that the anterior edge lay
on the anterior margin of the head of the caudate and the medial edge lay
on the border of the lateral ventricles. These methods have been described
in detail previously.28–30
The order of image acquisition was ﬁxed as follows: (1) structural MRI, (2)
parietal voxel, (3) basal ganglia voxel, (4) DLPFC voxel and (5) phantom.
The total scan time was ~ 45min.
Data processing. [1H]MRS spectra were processed using LCModel soft-
ware version 6–1–0 (Stephen Provencher Inc., Oakville, ON, Canada).
LCModel uses a linear combination of model spectra of metabolite
solutions in vitro to analyse the major resonances of in vivo spectra. In this
case, a basis set of alanine, aspartate, Cr, gamma-aminobutyric acid,
glutamine, glutamate, glycerophosphocholine, myo-inositol, lactate, NAA,
N-acetyl-aspartylglutamate (but note, we here report NAA+N-acetyl-
Figure 1. Location of voxels of interest (VOIs). VOIs were positioned in (a) left basal ganglia (20x20 × 15mm3) to include the head of the
caudate, putamen and internal capsule; (b) left dorsolateral prefrontal cortex (16x24× 20mm3); and (c) left medial parietal lobe (20x20 × 20
mm3).
Figure 2. Example of an 1.5 Tesla proton magnetic resonance spectroscopy ([1H]MRS) spectrum showing LCModel 6–1–0 ﬁt. This spectrum
was acquired from the dorsolateral prefrontal cortex voxel (DLPFC).
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aspartylglutamate combined as ‘NAA’ for simplicity), scyllo-inositol and
taurine, together with a baseline function were used for analysis.
Calculation of absolute metabolite concentrations. Metabolite concentra-
tions for NAA, Cr, Glx and Cho were calculated, in institutional units, as
follows. Raw estimates (LCModel output) were corrected by reference to
calibration data from a phantom containing an aqueous solution of known
NAA concentration. A phantom [1H]MRS spectrum was acquired at the end
of each scanning session. The ratio of the known concentration of NAA in
the phantom to the observed NAA phantom concentration was used to
derive a correction factor that was applied to calibrate the metabolite
concentrations into molar units. This served to control for possible scanner
‘drift’ in raw [1H]MRS estimates. See Figure 2 for an example LCModel ﬁt of
one of the spectra included in this study.
To guard against partial volume confounds (group differences in
proportions of grey matter, white matter and cerebrospinal ﬂuid (CSF) in
the [1H]MRS voxels), we also corrected the metabolite concentrations for
voxel composition. We ﬁrst determined the percentage of grey matter,
white matter and CSF within each [1H]MRS voxel for each participant by
segmenting the SPGR structural volume, using an automated procedure,
spm_segment, part of the Statistical Parametric Mapping software package
(http://www.ﬁl.ion.ucl.ac.uk/spm/).
The position of each individual [1H]MRS voxel relative to the
corresponding structural image was determined using positional coordi-
nates embedded in the spectra data ﬁles. The % grey, white and CSF
composition of each voxel was then calculated automatically from the
segmented images using in-house software. Finally, metabolite concentra-
tions were corrected for voxel % (CSF) by multiplying values by an
individual correction factor = 1/(1− ProportionCSF), where ProportionCSF
could range from 0 to 1.
In summary, Metabolitecorrected =Metaboliteraw × (PhantomNAAknown/
PhantomNAAobserved) × (1/(1–ProportionCSF)).
Statistical analysis. All statistical analysis was performed using SPSS 15.0
(SPSS, Chicago, IL, USA).
First, participant demographic information for the groups was compared
using χ2 analyses and one-way analyses of variance across the three
participant groups, namely, stimulant-naive ADHD participants, medicated
ADHD participants and healthy controls.
Voxel tissue composition was compared using independent samples
t-tests comparing participants with ADHD (n= 40) with the healthy controls
(n=20) for each of (i) grey matter, (ii) white matter and (iii) CSF in each
voxel. We further compared the two ADHD groups, ADHD naive and ADHD
medicated, with independent samples t-tests.
The primary [1H]MRS analysis was a series of independent samples t-
tests comparing all participants with ADHD (n= 40) to the matched healthy
controls (n=20), for each corrected metabolite value (four), in each voxel
(three). As this analysis involved multiple (12) comparisons, we performed
a Bonferroni correction raising the signiﬁcance threshold for each
comparison from P= 0.05 to P=0.004. We report results both before and
after the Bonferroni correction.
In order to test for the possibility of medication effects on metabolites,
we compared the two ADHD groups, ADHD naive and ADHD medicated,
with independent samples t-tests. We further compared metabolite values
in those ADHD participants who had never been prescribed any prescribed
psychoactive medication in the past to healthy controls to verify the
absence of any possible medication confounds.
We explored possible correlations between metabolite abnormalities
and symptom severity in stimulant-naive participants with ADHD. We
calculated bivariate Pearson’s correlations between those metabolite
concentrations that were signiﬁcantly (at Po0.05 Bonferroni corrected)
different from controls, and self-reported total Barkley Scale Inattention
and Hyperactivity symptom scores.
Finally, to verify that our results were not artefacts of differences in the
quality of the spectra, we examined group differences in % Cramer–Rao
Lower Bounds (%CRLBs) for each metabolite for each voxel. Higher %CRLBs
indicate greater uncertainty in metabolite estimation.
RESULTS
Participant group characteristics
Participant characteristics are given in Table 1. There were no
signiﬁcant differences in age or full-scale IQ (P>0.05) across the
participant groups. The two patient groups did not differ in mean
symptom severity. The mean duration of stimulant treatment in
the ADHD-medicated group (n= 16) was 86 weeks at the time of
scanning (s.d. = 180, range = 1–624 weeks).
Primary analysis
Basal ganglia. ADHD participants had a signiﬁcantly lower concen-
tration of Glx, Cho, Cr and NAA with all except Cho surviving
Bonferroni correction for multiple comparisons (Table 2 and Figure 3).
DLPFC. Individuals with ADHD had signiﬁcantly lower Glx, Cr and
NAA; however, only the difference in Cr survived Bonferroni
correction.
Table 2. [1H]MRS data
Healthy control ADHD P1-value P2-value
Total Medicated Not medicated
Basal ganglia
Cho 1.27 (0.27) 1.12 (0.2) 1.13 (0.18) 1.11 (0.59) 0.043* 0.966
Cr 6.18 (1.32) 5.19 (0.56) 5.21 (0.58) 5.18 (0.56) 0.001** 0.996
NAA 6.48 (1.34) 5.27 (0.75) 5.22 (0.48) 5.31 (0.90) 0.000** 0.966
Glx 11.94 (1.7) 10.61 (1.0) 10.4 (1.21) 10.7 (0.82) 0.002** 0.727
Dorsolateral prefrontal cortex
Cho 1.24 (0.3) 1.09 (0.12) 1.06 (0.14) 1.11 (0.10) 0.040* 0.701
Cr 4.37 (0.75) 3.85 (0.29) 3.85 (0.36) 3.86 (0.25) 0.001** 0.999
NAA 6.38 (1.18) 5.71 (0.44) 5.69 (0.53) 5.72 (0.39) 0.006* 0.994
Glx 7.84 (1.43) 7.42 (0.87) 7.44 (1.15) 7.41 (0.65) 0.261 0.994
Parietal cortex
Cho 1.03 (0.23) 0.95 (0.17) 0.91 (0.16) 0.97 (0.17) 0.234 0.604
Cr 4.86 (0.64) 4.67 (0.57) 4.61 (0.55) 4.71 (0.58) 0.365 0.842
NAA 7.14 (1.03) 6.56 (0.54 ) 6.44 (0.56) 6.64 (0.53) 0.022* 0.699
Glx 10.13 (1.74) 9.03 (1.40) 9.45 (1.44) 8.76 (1.33) 0.060 0.342
Abbreviations: [1H]MRS, proton magnetic resonance spectroscopy; ADHD, attention-deﬁcit hyperactivity disorder; Cho, choline; Cr, creatine plus
phosphocreatine; Glx, glutamate and glutamine; NAA, N-acetylaspartate. Data are given as mean (s.d.); *signiﬁcant at Po0.05, uncorrected for multiple
comparisons; **signiﬁcant at Po0.05 after conservative Bonferroni correction for multiple (12) comparisons. P1, controls vs ADHD (both stimulant naive and
medicated) t-test; P2, ADHD naive vs ADHD medicated.
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Parietal lobe. Only NAA was altered in ADHD in this voxel; this
did not survive Bonferroni correction.
Secondary analyses
Voxel composition. There were no signiﬁcant differences
between the ADHD and control groups in the mean tissue
composition of the [1H]MRS voxels for grey matter, white matter
or CSF (Table 3) in either the basal ganglia or DLPFC voxels. In the
parietal voxel, there was a small but signiﬁcant (Po0.05)
difference in % CSF only. Nevertheless, because all metabolite
concentrations were corrected for voxel % CSF (see Materials and
methods), this is unlikely to have affected our results. There were
no differences between the ADHD-naive and ADHD-medicated
groups in any region (P>0.35).
Spectrum quality. Across the three voxels and the four metabo-
lites, analyses of variance revealed no signiﬁcant group differences
in % CRLB, except in Glx in the DLPFC voxel where they differed
signiﬁcantly (P= 0.004); here, the healthy controls had higher %
CRLB, indicating worse data quality. As this was the only instance
in which quality differed, and as the ADHD patients (the group
with lower estimates) had better quality than the controls in this
case, we are conﬁdent that our ﬁndings of reduced concentrations
of various metabolites in ADHD patients are not an artefact of
group differences in data quality leading to globally biased
measures. See Table 4 for details.
Effect of stimulant medication. There were no signiﬁcant differ-
ences between ADHD-naive and ADHD-medicated participants in
any metabolite value, in any region (all P>0.139), even without
correcting for multiple comparisons (Table 2). We further
compared metabolite values in ADHD participants with no prior
or current use of any prescribed psychoactive medication (n= 15),
including stimulants or any other drug classes, with the healthy
controls (n= 20). The basal ganglia Glx, Cr and NAA, and DLPFC Cr,
were still signiﬁcantly reduced (Po0.05 uncorrected), conﬁrming
most ﬁndings despite a reduced sample size.
Metabolites and symptoms. An exploratory analysis of symptom
dimensions in stimulant-naive ADHD participants revealed that
the concentration of Glx in the basal ganglia voxel was negatively
correlated with total Barkley Scale Inattention score (n= 24, r=
− 0.610, P= 0.004), with lower (more abnormal) Glx concentrations
associated with more severe symptoms of inattention (Figure 4).
However, we observed no signiﬁcant correlation between basal
Figure 3. Comparison of glutamate/glutamine (Glx) in basal ganglia, dorsolateral prefrontal cortex (DLPFC) and parietal cortex voxels in
healthy control participants and participants with attention-deﬁcit hyperactivity disorder (ADHD). All concentrations are in institutional
absolute units.
Table 3. Voxel composition by group
Healthy control ADHD P1-value P2-value
Total Medicated Not medicated
Basal ganglia
Grey 0.70 (0.12) 0.72 (0.083) 0.71 (0.06) 0.73 (0.098) 0.406 0.542
White 0.37 (0.12) 0.33 (0.08) 0.34 (0.06) 0.33 (0.09) 0.221 0.690
CSF 0.008 (0.01) 0.007 (0.01) 0.007 (0.01) 0.008 (0.01) 0.886 0.906
Dorsolateral prefrontal cortex
Grey 0.28 (0.10) 0.25 (0.06) 0.24 (0.04) 0.26 (0.07) 0.156 0.453
White 0.75 (0.10) 0.78 (0.07) 0.78 (0.05) 0.77 (0.08) 0.297 0.660
CSF 0.017 (0.01) 0.014 (0.01) 0.014 (0.01) 0.014 (0.01) 0.340 0.959
Parietal cortex
Grey 0.45 (0.05) 0.47 (0.07) 0.48 (0.08) 0.47 (0.06) 0.184 0.690
White 0.51 (0.08) 0.5 (0.08) 0.48 (0.09) 0.51 (0.06) 0.591 0.373
CSF 0.09 (0.04) 0.069 (0.03) 0.074 (0.03) 0.066 (0.03) 0.022* 0.388
Abbreviations: ADHD, attention-deﬁcit hyperactivity disorder; CSF, cerebrospinal ﬂuid. Data are given as mean (s.d.). Values represent estimated mean
proportion of voxel (range 0–1). P1, controls vs ADHD (both stimulant naive and medicated) t-test; P2, ADHD naive vs ADHD medicated. These showed no
signiﬁcant differences except in parietal cortex % CSF (Po0.05) that was signiﬁcantly higher in the healthy controls compared with the ADHD groups, with no
differences between the medicated and medication naive ADHD groups. * indicates that the comparison was signiﬁcant at Po0.05.
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ganglia Glx and hyperactive symptoms (r= 0.247, P= 0.294) or
between basal ganglia Cr, basal ganglia NAA and DLPFC Cr, and
any other symptoms (all P>0.13).
Past psychiatric comorbidity. As speciﬁed above, 22 of the 40
ADHD patients reported at least one past psychiatric comorbidity
(though none had a current comorbidity), whereas none of the
controls did. To verify that psychiatric history did not inﬂuence our
MRS ﬁndings, we ran a series of independent group t-tests
comparing ADHD-past-comorbid vs ADHD-never-comorbid
patients for each of the four metabolites in the three regions
(n=40). There was no signiﬁcant difference on any MRS metabolite
in any region (12 tests; all P-values >0.141 uncorrected).
DISCUSSION
We report signiﬁcantly reduced concentrations of glutamate/
glutamine (Glx) in the caudate/putamen of adults with ADHD,
compared with matched healthy controls as measured using [1H]
MRS. We also observed reductions in Cr and NAA in this region in
the ADHD group, as well as reduced Cr in the DLPFC.
It is likely that these reductions represent a primary correlate of
ADHD, rather than being secondary to medication effects, because
we observed no differences between ADHD patients who were
receiving stimulant medication compared with those who were
medication naive. Also, our ﬁndings are not accounted for by
differences in voxel grey/white matter proportion or by participant
age, sex and IQ.
Furthermore, we are conﬁdent that our ﬁnding of reduced
concentrations of certain metabolites in ADHD does not reﬂect
group differences in data quality. Those metabolite levels that had
differences that survived Bonferroni correction did not differ in
precision as estimated with %CRLB, which suggests that our
results cannot be explained as a result of, for instance, degraded
spectra due to increased within-scanner motion in the ADHD
group reﬂecting hyperkinesis or ‘ﬁdgeting’.
Our data therefore add to an emerging literature on neuro-
chemical abnormalities in adults with ADHD. Our ﬁnding of
reduced Glx in the caudate/putamen is complemented by other
studies that reported reduced Glx in the anterior cingulate cortex
and the medial PFC.17,19 However, this reduction probably does
not affect whole brain, because we observed no signiﬁcant
differences in the DLPFC or the parietal ‘control’ region in the
current study, and increased glutamate has previously been
reported in the cerebellum of ADHD adults.18
Therefore, reduced Glx in adults with ADHD is not a brain-wide
phenomenon, but seems to be affecting particular neural circuits.
The reduction in Glx may also be age dependent, as studies in
ADHD children have reported increased Glx, including signiﬁcant
increases in the frontal cortex31–33 and signiﬁcant34 or nearly
signiﬁcant31 increases in the striatum (although see Yeo et al.35
and Sun et al.36).
Our results thus add to emerging evidence that ADHD is
associated with glutamate pathway abnormalities at least in some
cases. This evidence includes the discovery of rare deleterious
Table 4. Mean metabolite estimated precision (%CRLB) by group for each of four metabolites in three voxels
Control
mean (s.d.)
ADHD P-value
Total Medicated Not medicated
mean (s.d.) mean (s.d.) mean (s.d.)
Basal ganglia
Cho 0.095 (0.026) 0.097 (0.027) 0.089 (0.018) 0.104 (0.032) 0.279
Cr 0.071 (0.019) 0.071 (0.014) 0.068 (0.009) 0.073 (0.016) 0.581
NAA 0.100 (0.028) 0.109 (0.023) 0.106 (0.022) 0.111 (0.025) 0.393
Glx 0.097 (0.04) 0.100 (0.044) 0.086 (0.012) 0.111 (0.056) 0.194
DLPFC
Cho 0.075 (0.018) 0.067 (0.011) 0.068 (0.012) 0.066 (0.011) 0.161
Cr 0.067 (0.013) 0.061 (0.008) 0.063 (0.009) 0.06 (0.008) 0.120
NAA 0.072 (0.017) 0.067 (0.012) 0.067 (0.011) 0.067 (0.013) 0.456
Glx 0.144 (0.056) 0.103 (0.033) 0.099 (0.033) 0.105 (0.034) 0.004
Parietal cortex
Cho 0.089 (0.015) 0.091 (0.015) 0.093 (0.016) 0.090 (0.015) 0.654
Cr 0.066 (0.012) 0.065 (0.01) 0.068 (0.012) 0.063 (0.009) 0.511
NAA 0.072 (0.012) 0.075 (0.015) 0.076 (0.017) 0.074 (0.014) 0.671
Glx 0.092 (0.02) 0.101 (0.042) 0.095 (0.023) 0.105 (0.053) 0.488
Abbreviations: ADHD, attention-deﬁcit hyperactivity disorder; Cho, choline; Cr, creatine; %CRLB, % Cramer–Rao Lower Bounds; DLPFC, dorsolateral predfrontal
cortex; Glx, glutamate and glutamine; NAA, N-acetylaspartate. Data are given as mean (s.d.). P-value: two-tailed t-test for analysis of variance comparing
control; ADHD medicated and ADHD naive groups by %CRLB.
Figure 4. Absolute concentration of glutamate/glutamine (Glx) in
the basal ganglia voxel was negatively correlated with total Barkley
Scale Inattention score (r=− 0.610, P= 0.004), with lower (more
abnormal) Glx concentrations associated with more severe symp-
toms of inattention. Scatterplot shows data points with linear
correlation and 95% mean conﬁdence intervals. Glx concentration is
in institutional units.
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variants in metabotropic glutamate receptors and other related
genes in a minority of ADHD cases37 and also from animal
models.38 This evidence has led to the development of glutamate
modulatory drugs as potential treatments for ADHD, including the
novel AMPA receptor-positive modulator Org26576, which was
recently shown to be effective in a preliminary trial.10 Our data
suggest that, at least in adults, the caudate/striatum may be the
most important region implicated in glutamate dysfunction
in ADHD.
As well as reduced Glx, we found reduced NAA and Cr in the
caudate and putamen, and reduced Cr in the DLPFC. This
contrasts with two prior [1H]MRS studies of adult ADHD that
found reduced NAA in the DLPFC,16 and no differences in Glx16 or
increased Glx:Cr ratio39 (with no absolute Glx reported) in the
caudate and striatum. However, these two studies were small
(n= 5 (ref. 16) and 10 (ref. 39) ADHD patients, respectively) and did
not include a ‘control’ region. Thus, it is not clear that they
possessed the statistical power to detect the effects were
observed.
The metabolic abnormalities we detected, primarily in the
caudate/putamen, may help to explain some of the core
symptoms of ADHD, because this brain area is known to have a
key role in the regulation of attention. For example, the basal
ganglia are activated during the performance of set-shifting,
reversal learning and task-switching paradigms,22 and in modulat-
ing the top-down inﬂuence of the PFC during shifts of attention.23
Consistent with its role in the ﬂexible control of attention, we
observed a signiﬁcant correlation between caudate/striatum Glx
and the Barkley Scale measure of the severity of attentional
deﬁcits, with lower, that is, more abnormal Glx being associated
with worse attentional impairment, but only in individuals who
were unmedicated. In medicated participants, although Glx was
lowered to the same extent, there was no correlation with
inattention, raising the possibility that dopaminergic stimulants
may compensate for, but not reverse, an underlying glutamatergic
abnormality. Although, given that this correlation is an exploratory
post hoc ﬁnding, it should be treated with caution.
What might be the origin of the reduction in Glx that we
observed in adult ADHD? It could be a primary deﬁcit.
Alternatively, it may be secondary to abnormalities in other
neurotransmitter systems that we were unable to measure in this
study. Dopamine pathways, for instance, richly innervate the
caudate and putamen, and they area key site of dopamine–-
glutamate interactions.40
Dopamine is also known to regulate glutamatergic cell ﬁring
and vice versa.40 As ADHD is classically linked to a dopamine
deﬁcit,5,6 it is possible that, at least in some cases of the disorder,
this is associated with changes in Glx. This could also explain the
ﬁndings of reduced Glx in the medial PFC and anterior cingulate
cortex (see above), as these areas are, similar to the basal ganglia,
major targets of dopamine.
Another possibility is that differences in Glx might be secondary
to abnormal cellular metabolism. For instance, we also observed
signiﬁcantly reduced concentrations of Cr and NAA, in the basal
ganglia voxel and of Cr in the DLPFC. This could indicate
decreased neuronal metabolism and energy use, as both Cr/PCr
and N-acetylaspartate ([1H]MRS Cr and NAA peaks, respectively)
are involved in neuronal energy metabolism.41,42 Such an energy
deﬁcit would be in line with glucose metabolism studies in adults
with ADHD that have shown reduction of metabolism in both
hemispheres.43
However, an alternative possible basis for reductions in Cr and
NAA is reduced neuronal density. We did not observe differences
in the voxel compositions of grey and white matter in the basal
ganglia and DLPFC, showing that these metabolite differences
were not simply partial volume effects caused by different
proportions of brain tissue. However, it is possible that there
were fewer (glutamatergic) neurons per unit of volume, leading to
reduced estimates of these neuronal metabolites. Unfortunately,
we are not aware of any studies that have examined neuronal
density in the basal ganglia in ADHD.
Our study has a number of limitations. We obtained [1H]MRS
data at a relatively low ﬁeld strength of 1.5 Tesla. This could have
limited the signal-to-noise ratio of our measures and, hence, it is
possible that there exist further metabolite differences beyond the
ones that we detected. Furthermore, we are unable to say whether
the reliability of this 1.5T MRS compares with that obtained at
higher ﬁeld strengths. However, we do not believe that this
undermines the robustness of those differences we did observe,
rather it suggests that those differences we found are likely to be
meaningful, as they can be detected even at 1.5 Tesla.
Another limitation arising from our use of 1.5 Tesla [1H]MRS is
that we were unable to distinguish between the compounds that
contribute to the ‘Glx’ signal, that is, glutamate and glutamine, as
their proton resonance signals overlap at low ﬁeld strengths.
Although glutamine is not directly involved in neurotransmission,
it serves as an intermediate in the recycling of glutamate after its
release and reuptake. Therefore, the glutamate:glutamine ratio
may provide important information about the rate of glutamate
synthesis and turnover.44 To understand the nature of the Glx
abnormalities seen in ADHD, future work should therefore use
higher ﬁeld strength MRS (3 or 7 Tesla) to measure glutamate and
glutamine separately.
A further issue is that we were not able to directly investigate
the effects of medication on neural metabolites in ADHD, because
patients were not examined before and after their treatment. We
do not think that medication effects inﬂuenced our results,
because we found no differences between adults with ADHD
currently taking medication as compared with medication-naive
adults. It is possible, however, that effects on neurometabolites
might be dose-dependent; however, we did not have access to
information on the prescribed dosage in those individuals who
were taking stimulants. Therefore, an additional limitation of our
study is that we were unable to examine possible dose-related
effects and we cannot exclude the possibility that treatment with
high doses of stimulants does exert an effect.
Finally, although our study included a ‘control’ region, the
medial parietal cortex, on the basis that it has not classically been
implicated in ADHD, some recent functional imaging studies have
reported alterations in activation in this area in ADHD.45 Thus, it
may not be unrelated to the pathophysiology of the disorder.
However, as we did not observe any (corrected) signiﬁcant
neurochemical differences in this area, the parietal data none-
theless support the regional speciﬁcity of the other ﬁndings.
In conclusion, adults with ADHD have regionally speciﬁc
reductions in glutamate/glutamine and the neuronal energy
metabolites NAA and Cr. Also reduction in striatal glutamate/
glutamine is associated with more severe symptoms of inattention
in medication-naive individuals. Glutamate may be a tractable
treatment target is some adults with ADHD.
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